natgillin/translations-raw huggingface dataset:
Long-term treatment:
Dolgotrajno zdravljenje:
long-term use of laxatives (to treat constipation)
dolgotrajna uporaba odvajal (za zdravljenje zaprtja)
Long-term use of Repatha demonstrated a sustained treatment effect as evidenced by reduction of LDL-C in patients with severe familial hypercholesterolaemia (table 5).
Dolgotrajna uporaba zdravila Repatha je imela trajen terapevtski učinek, kot je pokazalo znižanje LDL-H pri bolnikih s hudo družinsko hiperholesterolemijo (tabela 5).
long-term use, should only
dolgotrajno uporabo,
longer
dovoljenja
longer
za
longer
za za
longer authorised longer authorised
za promet za promet
Longer duration of seasonal prophylaxis up to 12 weeks has been evaluated in immunocompromised patients (see sections 4.4, 4.8 and 5.1).
Pri imunsko ogroženih bolnikih so proučevali preprečevanje sezonske gripe, ki je trajalo dlje časa, do 12 tednov (glejte poglavja 4.4, 4.8 in 5.1).
Longer eyelashes
daljše trepalnice,
Longer eyelashes (up to 45% of people)
daljše trepalnice (do 45 % ljudi),
longer longer
nima nima
longer longer
veā nima
longer longer
ťou ťou
Longer term therapy (48-54 months) resulted in stabilisation of GFR in male patients with normal baseline GFR (≥ 90 mL/min/1.73 m2) and with mild to moderate renal dysfunction (GFR 60 to < 90 mL/min/1.73 m2), and in slowing of the rate of decline in renal function and progression to end-stage renal disease in male Fabry patients with more severe renal dysfunction (GFR 30 to < 60 mL/min/1.73 m2).
Dolgotrajnejše zdravljenje (48–54 mesecev) je pri moških bolnikih z normalno izhodiščno vrednostjo GFR (≥ 90 ml/min/1,73 m2) in z blago do zmerno ledvično okvaro (GFR 60 do < 90 ml/min/1,73 m2) povzročilo stabilizacijo vrednosti GFR, pri moških bolnikih s Fabryjevo boleznijo s hujšo ledvično okvaro (GFR 30 do < 60 ml/min/1,73 m2) pa upočasnilo slabšanje delovanja ledvic in napredovanje do končne faze ledvične bolezni.
Longer term treatment with Soliris (median 55 weeks ranging from 1day to 107 weeks) was associated with an increased rate of clinically meaningful improvements in pediatric and adolescent patients with aHUS.
Dolgotrajnejše zdravljenje z zdravilom Soliris (mediana 55 tednov, razpon od 1 dne do 107 tednov) je bilo povezano z zvečano pogostnostjo klinično pomembnih izboljšanj pri pediatričnih in mladostniških bolnikih z aHUS.
longer uthorised longer uthorised
za promet za promet
longeruthorised longeruthorised
ťougistrácie ťougistrácie
Longmont, Colorado 80503 United States of America
Longmont, Colorado 80503 ZDA
Lonquex 6 mg solution for injection
Lonquex 6 mg raztopina za injiciranje
Lonquex 6 mg solution for injection in pre-filled syringe Lipegfilgrastim
Lonquex 6 mg raztopina za injiciranje v napolnjeni injekcijski brizgi lipegfilgrastim
Lonquex also compared well with the other medicine in the number of febrile neutropenia cases: 1 in the Lonquex-treated group versus 3 in the comparator group.
Zdravilo Lonquex je bilo z drugim zdravilom primerljivo tudi glede števila primerov febrilne nevtropenije: v skupini, ki je prejemala zdravilo Lonquex, je bil zabeležen 1 primer, v skupini s primerjalnim zdravilom pa 3.
Lonquex has been shown to be effective in reducing the duration of neutropenia and the number of febrile neutropenia cases among patients undergoing chemotherapy.
Zdravilo Lonquex je učinkovito skrajšalo trajanje nevtropenije in zmanjšalo število primerov febrilne nevtropenije med bolniki, ki so prejemali kemoterapijo.
Lonquex has no or negligible influence on your ability to drive and use machines.
Zdravilo Lonquex nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Lonquex is a medicine that contains the active substance lipegfilgrastim.
Lonquex je zdravilo, ki vsebuje zdravilno učinkovino lipegfilgrastim.
Lonquex is available as a solution for injection in pre-filled syringes.
Zdravilo Lonquex je na voljo v obliki raztopine za injiciranje v napolnjenih injekcijskih brizgah.
Lonquex is not used in patients receiving chemotherapy for chronic myeloid leukaemia (a cancer of the white blood cells) and myelodysplastic syndromes (a disease that can develop into a leukaemia).
Zdravilo Lonquex se ne uporablja pri bolnikih, ki prejemajo kemoterapijo zaradi kronične mieloične levkemije (raka belih krvničk) in mielodisplastičnega sindroma (bolezni, iz katere se lahko razvije levkemija).
Lonquex may be removed from the refrigerator and stored below 25 °C for a maximum single period of up to 3 days.
Zdravilo Lonquex lahko odstranite iz hladilnika in shranite pri temperaturi do 25 °C za največ enkratno 3-dnevno obdobje.
Lonquex may be removed from the refrigerator and stored below 25 °C for a maximum single period of up to 3 days.
Zdravilo Lonquex lahko vzamete iz hladilnika in shranite pri temperaturi do 25 °C za največ enkratno 3-dnevno obdobje.
Lonquex should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens.
Zdravila Lonquex ne smete uporabljati za povečanje odmerka citotoksične kemoterapije zunaj uveljavljenih shem odmerjanja.
Lonsurf 15 mg /6.14 mg film-coated tablets trifluridine/tipiracil
Lonsurf 15 mg/6,14 mg filmsko obložene tablete trifluridin/tipiracil
Lonsurf 15 mg is a white, biconvex, round, film-coated tablet, printed with “15” on one side and “102” and “15 mg” on the other side in grey ink.
Zdravilo Lonsurf 15 mg je v obliki belih, bikonveksnih, okroglih filmsko obloženih tablet s sivo oznako "15" na eni ter "102" in "15 mg" na drugi strani.
Lonsurf 15 mg tablet
Lonsurf 15-mg tableta
Lonsurf 15 mg/6.14 mg film-coated tablets
Lonsurf 15 mg/6,14 mg filmsko obložene tablete
Lonsurf 15 mg/6.14 mg film-coated tablets Lonsurf 20 mg/8.19 mg film-coated tablets
Lonsurf 15 mg/6,14 mg filmsko obložene tablete Lonsurf 20 mg/8,19 mg filmsko obložene tablete
Lonsurf 20 mg is a pale red, biconvex, round, film-coated tablet, printed with “20” on one side and “102” and “20 mg” on the other side in grey ink.
Zdravilo Lonsurf 20 mg je v obliki rdečih, bikonveksnih, okroglih filmsko obloženih tablet s sivo oznako "20" na eni ter "102" in "20 mg" na drugi strani.
Lonsurf 20 mg tablet
Lonsurf 20-mg tableta
Lonsurf 20 mg/8.19 mg film-coated tablets trifluridine/tipiracil
Lonsurf 20 mg/8,19 mg filmsko obložene tablete trifluridin/tipiracil
Lonsurf caused an increase in the incidence of myelosuppression including anaemia, neutropenia, leucopenia, and thrombocytopenia.
Zdravilo Lonsurf je povečalo pojavnost mielosupresije vključno z anemijo, nevtropenijo, levkopenijo in trombocitopenijo.
Lonsurf contains the active substances trifluridine and tipiracil.
Zdravilo Lonsurf vsebuje zdravilni učinkovini trifluridin in tipiracil.
Lonsurf has been shown to prolong overall survival of patients with metastatic colorectal cancer who previously received other treatments.
Dokazali so, da zdravilo Lonsurf podaljša skupni čas preživetja bolnikov z metastatskim kolorektalnim rakom, ki so predhodno prejemali druga zdravila.
Lonsurf has minor influence on the ability to drive and use machines.
Zdravilo Lonsurf ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
Lonsurf is a cancer medicine used to treat adults with metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
Zdravilo Lonsurf je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje odraslih z metastatskim kolorektalnim rakom (rakom debelega črevesa, ki se je razširil v druge dele telesa).
Lonsurf is comprised of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride, at a molar ratio 1:0.5 (weight ratio, 1:0.471).
Zdravilo Lonsurf sestavljata antineoplastični timidinski nukleozidni analog, trifluridin, in zaviralec timidin-fosforilaze (TPaze), tipiracilijev klorid, v molarnem razmerju 1:0,5 (masno razmerje 1:0,471).
Lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.
Zdravilo Lonsurf je indicirano za zdravljenje odraslih bolnikov z metastatskim kolorektalnim rakom (CRC – Colorectal Cancer), ki so bili predhodno že zdravljeni ali niso primerni za zdravljenja, ki so na voljo.
Lonsurf is not recommended for use in patients with moderate or severe hepatic impairment (National Cancer Institute [NCI] Criteria Group C and D) as Lonsurf has not been studied in these patients (see section 5.2).
Uporaba zdravila Lonsurf pri bolnikih z zmerno ali hudo jetrno okvaro ni priporočljiva (C in D skupini kriterijev Nacionalnega Inštituta za raka [NCI – National Cancer Institute]), ker zdravila Lonsurf pri teh bolnikih še niso preskušali (glejte poglavje 5.2).
Lonsurf is not recommended for use in patients with severe renal impairment or end-stage renal disease (creatinine clearance [CrCl] < 30 mL/min or requiring dialysis, respectively), as Lonsurf has not been studied in these patients (see section 5.2).
Zdravilo Lonsurf ni primerno za uporabo pri bolnikih s hudo ledvično okvaro (očistek kreatinina [CrCl – Creatinine Clearance] < 30 ml/min) ali končno stopnjo ledvične okvare (potrebna dializa), ker zdravila Lonsurf pri teh bolnikih še niso preskušali (glejte poglavje 5.2).
Lonsurf is used to treat adults with colon or rectal cancer - sometimes called ‘colorectal’ cancer.
Zdravilo Lonsurf uporabljamo za zdravljenje odraslih z rakom kolona ali rektuma – t.i. kolorektalnim rakom.
Lonsurf Placebo
Št. ogroženih: Lonsurf placebo
Lonsurf-treated patients who received prior radiotherapy vs. those that did not.
Predvsem pojavnost febrilne nevtropenije je bila v primerjavi z bolniki, ki niso bili obsevani, večja pri bolnikih, ki so prejemali zdravilo Lonsurf po predhodnem obsevalnem zdravljenju.
Lonza Biologics Inc., 101 International Drive, Portsmouth, NH 03801-2815, USA Name and address of the manufacturers responsible for batch release
Lonza Biologics Inc., 101 International Drive, Portsmouth, NH 03801-2815, ZDA Ime in naslov izdelovalcev, odgovornih za sproščanje serij
Lonza Biologics Porriño,S.L A Relva s/n
Lonza Biologics Porriño, S.L A Relva s/n
Look at the cartridge before you use it.
Vložek pred uporabo preglejte.
Look at the cartridge before you use the pen.
Preden uporabite injekcijski peresnik, preglejte vložek.
Look at the cartridge before you use the pen.
Vložek pred uporabo injekcijskega peresnika preglejte.
Look at the cartridge before you use the pen.
Vložek pred uporabo preglejte.
Look at the cartridge sealed in the disposable pen injector before you use it.
Pred uporabo preglejte vložek, zavarjen v injekcijski peresnik za enkratno uporabo.
Look at the expiry date on the box to be used.
Preverite rok uporabnosti na škatli.
Look at the expiry date on the pack and dose tray.
Preverite rok uporabnosti na pakiranju in podstavku z zdravilom.
Look at the expiry date on the pre-filled pen and pack.
Preverite rok uporabnosti na napolnjenem injekcijskem peresniku in na pakiranju.
Look at the expiry date on the syringe and pack.
Preverite rok uporabnosti na injekcijski brizgi in na pakiranju.
Look at the expiry date on the syringe.
Preverite datum izteka roka uporabnosti na brizgi.
Look at the expiry date on the vial.
Preverite datum izteka roka uporabnosti na viali.
Look at the final solution to check for particulate matter or discolouration.
Prepričati se morate, da pripravljena raztopina ne vsebuje vidnih delcev oziroma ni obarvana.
Look at the inhaler to make sure it is not damaged or dirty.
Preglejte inhalator in se prepričajte, da ni poškodovan ali umazan.
Look at the liquid in the syringe window (Figure 2).
Skozi okence preverite tekočino v injekcijski brizgi (slika 2).
Look at the liquid through the viewing window of the pre-filled syringe and make sure that it is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow.
Poglejte skozi opazovalno okence v napolnjeni injekcijski brizgi in se prepričajte, da je tekočina v njej bistra do rahlo opalescentna (tj. da ima biserni sij) ter brezbarvna do svetlo rumena.
Look at the medicine in the pre-filled syringe.
Zdravilo v napolnjeni injekcijski brizgi preglejte.
Look at the medicine through the viewing window.
Zdravilo preglejte skozi okence za pregledovanje.
Look at the used capsule.
Preglejte uporabljeno kapsulo.
Look at the vial before you use it.
Vialo pred uporabo preglejte.
Look at the vial before you use it.
Vialo preglejte, preden jo uporabite.
Look carefully at the reservoir holder.
Pozorno si oglejte prostor za tekočino.
Look closely at the tip of the needle for tiny drop(s) of fluid
Dobro opazujte, če na konici igle vidite majhne kaplje tekočine
LOOK FOR PARTICLES
PREGLEJTE GLEDE DELCEV
Look for the line that shows how much the adult or child/adolescent weighs.
Poiščite vrstico, v kateri je podana ustrezna telesna masa odraslega bolnika oziroma otroka ali mladostnika.
Look for the needle tip inside the stopper window (see Diagram 4).
Skozi okence v zamašku preverite, ali vidite konico igle (glejte sliko 4).
Look in the window.
Poglejte v okence.
Look into your child’s mouth to make sure that all the medicine has been swallowed.
Poglejte v otrokova usta, da preverite, ali je zaužil celotni odmerek zdravila.
Look out for any symptoms of infection or other symptoms such as:
Bodite pozorni na kakršne koli simptome okužbe ali druge simptome, kot so:
Look out for infections.
Bodite pozorni na okuţbe.
Look out for infections.
Bodite pozorni na okužbe.
look out for possible signs of lactic acidosis – see section 4, Possible side effects.
bodite pozorni na morebitne znake laktacidoze – glejte poglavje 4 Možni neželeni učinki;
Look out for serious side effects
Predklinični podatki o varnosti
Look out for side effects
Bodite pozorni na neţelene učinke
Look out for the following:
Bodite pozorni na naslednje:
Look out for the signs of allergy in 5 Possible side effects
Znaki alergije so opisani v poglavju 5.
Look through the oval display window.
Poglejte skozi ovalno okence.
Look through the transparent window to make sure that the plunger has moved to the bottom as indicated in the figure.
Poglejte skozi prozorno okence in se prepričajte, da se je bat premaknil do dna, kot prikazuje slika.
Look through the viewing window to check that the liquid in the cartridge is clear and free of solid particles.
Poglejte skozi opazovalno okence in preverite, da je tekočina v vložku bistra in brez trdnih delcev.
Look through the viewing window to make sure that the liquid in the pre-filled pen is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow.
Poglejte skozi opazovalno okence in se prepričajte, da je tekočina v napolnjenem injekcijskem peresniku bistra do rahlo opalescentna (tj. da ima biserni sij) ter brezbarvna do svetlo rumena.
Look to see if the capsule is empty - the capsule must spin in the inhaler in order to empty.
Preverite, ali je kapsula prazna – kapsula se mora vrteti v inhalatorju, da se izprazni.
Look to see that nothing is blocking the mouthpiece.
Preverite, ali ustnik kaj ovira.
Look up the child’s weight on the left side of the table.
Poiščite otrokovo telesno maso na levi strani preglednice.
Looking at the results of the studies together, 98% of patients (1,015 out of 1,035) taking Epclusa for 12 weeks tested negative for the virus 12 weeks after the end of treatment.
98 % bolnikov (1 015 od 1 035), ki so 12 tednov jemali zdravilo Epclusa, testi za virus 12 tednov po koncu zdravljenja negativni.
Looking at the results of the three main studies taken together, 34% of the patients adding Vimpat 200 mg/day and 40% of the patients adding Vimpat 400 mg/day to their existing treatment achieved at least a 50% reduction in the number of seizures.
Skupni rezultati vseh treh glavnih študij so pokazali, da se je pri 34 % bolnikov, ki so svojemu obstoječemu zdravljenju dodajali zdravilo Vimpat v odmerku 200 mg/dan, in pri 40 % bolnikov, ki so svojemu obstoječemu zdravljenju dodajali zdravilo Vimpat v odmerku 400 mg/dan, število napadov zmanjšalo za vsaj 50 %.
Looking at the results of the three studies taken together, Zebinix 800 mg and 1200 mg were more effective than placebo at reducing the number of seizures, when used as add-ons to other anti-epileptic medicines.
Upoštevajoč rezultate vseh treh študij sta bila 800-miligramski in 1 200-miligramski odmerek zdravila Zebinix uporabljena kot dodatek k drugim zdravilom k epilepsiji, učinkovitejša od placeba pri zmanjševanju števila napadov.
Looking at the results of the three studies together, over 18 months, patients who received Riluzole Zentiva 100 mg/day had an average survival time that was about two months longer than the survival time for patients who received placebo.
18 mesecev, je bil povprečni čas preživetja bolnikov, ki so dobivali zdravilo Riluzole Zentiva v odmerkih 100 mg/dan, za približno dva meseca daljši v primerjavi z bolniki, ki so dobivali placebo.
looking at the results of the two studies in nosocomial pneumonia taken together, 75% of the patients receiving Doribax were cured (195 out of 260), compared with 72% of the patients taking piperacillin/tazobactam or imipenem (174 out of 241); looking at the results of the two studies of complicated abdominal infections taken together, 85% of the patients receiving Doribax were cured (275 out of 325), compared with 84% of the patients receiving meropenem (260 out of 309); in complicated urinary tract infections, 82% of the patients receiving Doribax were cured (230 out of 280), compared with 83% of the patients receiving levofloxacin (221 out of 265).
skupni rezultati obeh študij, pri katerih so sodelovali bolniki z nozokomialno pljučnico, so pokazali, da je ozdravelo 75 % bolnikov (195 od 260), ki so prejemali zdravilo Doribax, v primerjavi z 72 % bolnikov (174 od 241), ki so prejemali piperacilin/tazobaktam ali imipenem; skupni rezultati obeh študij, pri katerih so sodelovali bolniki z zapletenimi trebušnimi okužbami, so pokazali, da je ozdravelo 85 % bolnikov (275 od 325), ki so prejemali zdravilo Doribax, v primerjavi s 84 % bolnikov (260 od 309), ki so prejemali meropenem; pri zapletenih okužbah sečil je ozdravelo 82 % bolnikov (230 od 280), ki so prejemali zdravilo Doribax, v primerjavi z 83 % bolnikov (221 od 265), ki so prejemali levofloksacin.
Looking at the results of the two studies taken together, 55% of the patients receiving Relistor opened their bowels within four hours after the first injection (91 out of 165), compared with 15% of the patients receiving placebo (18 out of 123).
Skupni rezultati obeh študij kažejo, da je 55 % (91 od 165) bolnikov, ki so prejeli zdravilo Relistor, odvajalo blato v štirih urah po prvem injiciranju v primerjavi s 15 % (18 od
Looking at the results of the two studies taken together, viral loads had fallen by an average of 99% after 24 weeks in the patients adding Celsentri to optimised background therapy, compared with 90% in those adding placebo.
Na podlagi rezultatov obeh študij je mogoče ugotoviti, da se je pri bolnikih, ki so poleg optimizirane osnovne terapije jemali zdravilo Celsentri, virusno breme po 24 tednih zmanjšalo v povprečju za 99 %, medtem ko se je pri bolnikih, ki so poleg optimizirane osnovne terapije jemali placebo, virusno breme v povprečju zmanjšalo za 90 %.
Looking at the results of the two studies together, 87% of the patients had complete remission (45 out of 52).
Pri pregledu rezultatov obeh študij skupaj je popolno remisijo doseglo 87 % bolnikov (45 bolnikov od 52).
Looking at the results of these follow-up studies together, 2 years after starting treatment 75% of patients who received Deltyba for 6 months or more had no bacteria in their sputum compared with 55% of patients who received Deltyba for 2 months or less.
Glede na skupne rezultate teh podaljšanih študij dve leti po začetku zdravljenja 75 % bolnikov, ki so zdravilo Deltyba prejemali šest mesecev ali več, ni imelo bakterij v izpljunku, v primerjavi s 55 % bolnikov, ki so zdravilo Deltyba prejemali dva meseca ali manj.
Looking at the two studies in adults together, the average viral load was 70,000 copies/ml at the start of the studies.
Ob primerjanju skupnih rezultatov obeh študij, izvedenih pri odraslih, je bila na začetku študij povprečna virusna obremenitev 70 000 kopij/ml.
looking flushed increased blood pressure
zardel izgled, zvišan krvni tlak.
Looking only at the ‘high need’ patients in this study, 30% of those receiving Raptiva responded to treatment, compared with 3% of those receiving placebo.
Če upoštevamo le bolnike z „visoko potrebo“ iz te študije, se je na zdravljenje odzvalo 30 % izmed tistih, ki so prejemali zdravilo Raptiva, v primerjavi s 3 % bolnikov, ki so prejemali placebo.
looking pale, feeling low in energy or tired
bledica, pomanjkanje energije ali utrujenost
Loose body in joint, Mobility decreased, Muscle atrophy, Osteoarthritis, Synovial cyst, Synovitis,
nestabilnost sklepa otrdelost sklepa, prosti deli v sklepu, zmanjšana gibljivost, atrofija mišic osteoartritis, sinovialna cista sinovitis,
Loose nails
uha koža1
loose or watery stools
mehko ali tekoče blato,
loose stools (diarrhoea)
mehko blato (driska),
loose stools (diarrhoea)
redko blato (driska)
loose stools (diarrhoea) feeling tired (fatigue)
mehko blato (driska), utrujenost.
Loose stools, nausea, vomiting, abdominal pain
neredna stolica, navzea, bruhanje, abdominalne bolečine
loose stools, passing dark tarry stool, sore throat, hiccups, belching
mehko blato, začasna temna katranasta stolica (blato), vnetje grla, kolcanje, spahovanje.
Loperamide 16 mg QD
Loperamid, 16 mg 1-krat na
Loperamide AUC ↓ 51%
AUC loperamida ↓ 51
Loperamide Cmax ↓ 61%
Cmax loperamida ↓ 61
Loperamide Cmax ↓ 61% Loperamide AUC ↓ 51%
AUC loperamida ↓ 51
Loperamide should be given until patient is without diarrhoea for at least 12 hours.
Loperamid je treba dajati, dokler bolnik ni brez driske vsaj 12 ur.
Loperamide was administered to 13 % of patients in 5 % of courses.
Loperamid je dobilo 13 % bolnikov v 5 % ciklusov.
Lopinavir (400 mg twice daily)/
lopinavir (400 mg dvakrat dnevno)/
Lopinavir - ritonavir:
imeprevir 200 mg/dan (ritonavir
Lopinavir 400 mg / Ritonavir 100 mg (CYP3A4/5 strong inhibitors and substrates)
Lopinavir 400 mg / Ritonavir 100 mg (močna inhibitorja in substrata CYP3A4/5)
lopinavir 400 mg and ritonavir 100 mg twice daily
lopinavir 400 mg in ritonavir 100 mg dvakrat na dan
Lopinavir and ritonavir levels may increase on stopping St John’s wort.
Koncentraciji lopinavirja in ritonavirja se lahko po prekinitvi jemanja šentjanževke zvišata.
Lopinavir and ritonavir levels may increase on stopping St John’s wort.
To se lahko pojavi tudi pri
Lopinavir AUC over a 12 hour dosing interval averaged 113.2 ± 60.5 μg•h/ml.
AUC lopinavirja med 12-urnim odmernim intervalom je bila v povprečju 113,2  60,5 gh/ml.
Lopinavir AUC over a 24 hour dosing interval averaged 206.5 ± 89.7 gh/ml.
AUC lopinavirja med 24-urnim odmernim intervalom je bila v povprečju 206,5 ± 89,7 g·h/ml.
Lopinavir AUC ↓ 0.78 (0.56-1.09)
AUC lopinavirja ↓ 0,78 (0,56-1,09)
lopinavir AUC ↓ 34%
lopinavir AUC ↓ 34
Lopinavir AUC ↓ 55%
AUC lopinavirja ↓ 55
Lopinavir AUC  0.78 (0.56-1.09)
AUC lopinavirja  0,78 (0,56-1,09)
Lopinavir binds to both alpha- 1-acid glycoprotein (AAG) and albumin, however, it has a higher affinity for AAG.
Lopinavir se veže na alfa-1-kisli glikoprotein (AKG) in na albumin, vendar ima večjo afiniteto za AKG.
Lopinavir boosted with ritonavir (4x200 mg/
Z ritonavirjem okrepljeni
Lopinavir can be used during pregnancy if clinically needed.
Koncentraciji lopinavirja in ritonavirja se lahko po prekinitvi jemanja šentjanževke povečata.
Lopinavir Cmax ↓ 0.86 (0.64-1.16)
Cmax lopinavirja ↓ 0,86 (0,64-1,16)
lopinavir Cmax ↓ 30%
lopinavir Cmax ↓ 30
Lopinavir Cmax ↓ 47%
Cmax lopinavirja ↓ 47
Lopinavir Cmax  0.86 (0.64-1.16)
Cmax lopinavirja  0,86 (0,64-1,16)
Lopinavir Cmin ↓ 0.45 (0.25-0.82)
Cmin lopinavirja ↓ 0,45 (0,25-0,82)
lopinavir Cmin ↓ 43%
lopinavir Cmin ↓ 43
Lopinavir Cmin ↓ 70%
Cmin lopinavirja ↓ 70
Lopinavir Cmin  0.45 (0.25-0.82)
Cmin lopinavirja  0,45 (0,25-0,82)
Lopinavir concentrations: similar to
Koncentracije lopinavirja:
Lopinavir concentrations: ↓ 30-40%
Koncentracije lopinavirja: ↓ 30–40